Medical Marijuana, Inc. Subsidiary HempMeds® Brazil Announces Prominent Coverage in Brazilian Newspapers After Legal Victory

Federal Judge in Brazil Orders the Government to Subsidize Payments for Real Scientific Hemp Oil™ (RSHO™) for Brazilian Citizen

SAN DIEGO, Oct. 24, 2017 — Medical Marijuana, Inc.(OTC:MJNA), the first-ever publicly traded cannabis company in the United States, announced today subsidiary HempMeds® Brazil has gained media attention in Brazilian newspapers after a Federal judge there ordered the government to subsidize payments for Real Scientific Hemp Oil™ (RSHO™) for a Brazilian citizen.

According to the article, the Federal Regional Court of the 4th Region (TRF4) ordered the Union and the state of Santa Catarina to subsidize payments for RSHO™ for a Florianópolis merchant.

The article states that: “The trader appealed to the court, arguing that the use of the drug is essential, that efficacy is proven in such cases and that the right to health is fundamental and guaranteed by the Constitution. The court’s rapporteur, federal judge Rogerio Favreto, stated in his vote that the interference of the judiciary in drug applications, even if it is an exception, should occur if the patient’s need is proven. The judge pointed out that in the case under analysis the urgency is evident and has been proven by medical expertise.”

“We continue to be impressed and humbled by the amazing, historic gestures by the judicial system and federal government regulators in Brazil acting in the best interests of the health and wellness of the Brazilian people,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “This amazing progress in the Brazilian courts reaffirms our mission to keep educating the world about the beneficial nature of hemp-based cannabidiol (CBD) products such as RSHO™.”

This is the second recent case in which a Federal Justice has ordered that the Brazilian government should subsidize payments for CBD in Santa Catarina. In July of this year, a ruling also granted a child from Blumenau the right to free treatment with CBD. Also in February 2015, a young Santa Catarina girl named Amanda Dalagnol, Dionísio Cerqueira, in the West of SC, was awarded in court the right to government-subsidized CBD treatments.

About HempMeds Brasil™

HempMeds Brasil™ currently has three cannabis products approved for importation into Brazil as a prescription medication for Epilepsy, Parkinson’s and Chronic Pain. The company had the first-ever cannabis product allowed for import into Brazil and its products are currently subsidized by the Brazilian government, under their health care system, for all three medical indications listed above. HempMeds Brasil™ is working on additional approvals for multiple indications.

About Medical Marijuana, Inc.

We are a company of firsts®. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.

To see Medical Marijuana, Inc.’s video statement, click here.

Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.

FORWARD-LOOKING DISCLAIMER AND DISCLOSURES

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.

The statements in this press release have not been evaluated by the Food and Drug Administration (FDA) and are not intended to diagnose, treat or cure any disease. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act. The Company does sell and distribute hemp-based products.

CONTACT:

Public Relations Contact:

Andrew Hard

Chief Executive Officer

CMW Media

P: 888-829- 0070

[email protected]

www.cmwmedia.com

LATEST NEWS